r;-
`
`® ‘0)
`
`Euronilsches Patentamt
`
`' European Patent Office
`
`Office européen des brevets .
`
`® Pubiieation number:
`
`1
`
`0 235 796
`
`A2
`
`®
`
`.-
`
`'
`
`EUROPEAN PATENT-APPLICATION
`
`® Appiication number: 871029831
`
`@ Date or filing: 0303.87
`
`®_ Int. Cl.4- 007D 313/12, 007D 405/06,
`C07D 405/12, A61 K 31/335
`
`
`@ Priority: 03.03.85 JP 45676/86
`® Arapnpam: KYOWA HAKKO KOGYO CO., LTD.
`.
`-
`6-1,.Ohte-Machi ttchome
`'
`@ Date of publication of application:
`. Chiyoda-ku Tokyo(JP)
`09.09.87 Bulletin 07/37
`
`-
`
`L. Designated Contrading States:
`BE CH DE ES FR GB IT LI NL
`-
`
`.
`
`EP0235796A2
`
`(79 inventor: Oshima, Etsuo c/o KYOWA HAKKO
`KOGYO CO., LTD'
`_
`»
`Patent Dept. 6-1 Oht'ejmachl itchome
`Chiyoda-ku Tokyo(JP)
`inventor: Kumazawa, Tdshiakl c/o KYOWA
`HAKKO KOGYO co.. LTD
`‘
`Patent Dept. 6-1 Ohtemachi Itchome
`‘ Chlyoda-ku Tokyo(JP)
`Inventor: Otaki, Shizuo c/o KYOWA HAKKO .
`KOGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi ltchomé
`Chiyoda-ku Tokyo(JP)
`‘
`inventor: Obase, Hiroyuki c/o KYOWA HAKKO
`KOGYO CO., LTD
`Patent Dept. 6-1 Dhtemachi ttchorne
`Chiyoda-ku Tokyo(JP)
`inventor: thori, Kenji c/o KYOWA HAKKO
`KOGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi ltchome
`'Chiyoda--ku Tokyo(JP)
`Inventor. tshii, Hidee c/o KYOWA HAKKO
`KOGGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi ltchome
`Chiyoda-ku Tokyo(JP)
`inventor: Manabe, Haruhiko c/o KYOWA
`HAKKO KOGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi itchome
`Chiyoda-ku Tokyo(JP)
`inventor: Tamura, Tadafumi c/o KYOWA
`HAKKO KOGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi itchome
`Chiyoda-ku Tokyo(JP)
`Inventor: Shuto, Katsuichi c/o KYOWA HAKKO
`KOGYO CO., LTD
`Patent Dept. 6-1 Ohtemachi ltchome
`Chiyoda-ku Tokyo(JP)
`
`'
`
`@ Representative: Casalonga, Axel et al
`BUREAU D.A. CASALONGA - JOSSE
`MorassistrasSe 8
`13-8000 Munich 5(DE)
`Xerox Copy Centre
`
`Ayla Pharma LLC (11311202000295) EX. 1035 p. 001
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 001
`
`

`

`
`
`0 235 796
`
`® Dibenz me] oxepin derivative and antiallergic and antiintlammatory agent.
`
`@ Novel dibenz[b.e}oxepin derivatives are employed in the treatment and control of allergic conditions such as
`energic asthma and also emptoyed in the treatment of inflammation.
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 002
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 002
`
`

`

`0 235 796
`
`DIBENZIb,e]OXEPlN DERIVATIVE AND ANTIALLERGIC AND ANTIINFLAMMATORY AGENT
`
`Background 9! the invention
`
`5
`
`ll-hydroxy or il'-oxodibenz[b.e]oxepin derivative is
`it has been knewn that ll-unsubstituted.
`Heretoiore.
`used for antiinilammatory agents [J. Med. Chem. g, 633 -639 0978)].
`‘
`Further. it is known that dibenz{b.e]oxepin derivative wherein substitutents Ra and Rb at lbposiiion have '
`the following definitions, is employed in the treatment and control of allergic conditions (USP 4.282.365).
`Ra: _H OH, lower alkoxy. lower alkylthio, lower alkylsultinyl. lower alkylsullonyl, arylthio. NH,, NHCHO or
`imidazolyl:
`-
`w ' Rb: H or lower alkyl;
`or Ra and Rb taken together are = 0 =CHFtc wherein RC is H or aryl.
`Furthermore it is known that Il--(4-methylpiperazino) dibenzlb.e]oxepin derivative has an antiasthmatic
`activity (USP 4,396550 USP 4.465835. EP--A-3856)
`it is also known that dibenzIb.e]oxepin derivative having the following formula:
`
`15
`
`.
`
`2D
`
`s/VNRaRe
`
`wherein Rd and Re are lower alkyl and Rf is lower alkyl or halogen has an antiasthmatic activity (EP-A-
`85870)
`'
`.
`Diben2[b.e]oxepin derivative having an antiallergic activity and having the following structural formula:
`.
`s
`
`_
`
`0- (CH2) rNRth
`
`R1
`
`25
`
`30
`
`as
`
`wherein Fig and Rh are alkyl. r is 2 or 3 and Hi is ’alkyl‘ or halogen is known (JP-A-227879/84).
`Dibenz[b,e]oxepin derivative having an antlailergic activity and having the following structural formula;
`
`. 40
`
`_
`
`V
`
`Rj'
`
`45
`
`5"
`
`:
`
`o @
`
`Rk
`
`is ~NH~, -S-or -O-s
`wherein R ,- is 4-a-lkylpiperazino. 3~quinuclidylamino or -Xa-(CH,) s-NFizFlm wherein x;
`is 2 or 3 and R1 and Rm are alkyl and Fl.‘ is ON, 5.tetrazolyl CONH, or CO,Fl.. wherein Rn is H. alkyl or I-
`(ethoxycarbonyloxy)ethyl is known (EP-Al30555)
`Doxepin having an antidepressant activity and having the following structural formula is known [Drugs
`l3. l6l 0977.)].
`
`Ayla Pharma LLC (11311202000295) EX. (1035 p. 003
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 003
`
`

`

`0 235 798
`
`[In A\1
`Dothiepin having an antidepressant activity and having the following structural formula is known (Arz.-
`Forschg !039 (I953), ibid.. L4 m We.“
`
`NiMe)2
`
`m”
`
`.
`
`s
`
`o o
`As the compound having both an antiallergic activity and an antiinflammatory‘activity. steroids are
`
`known.
`lt is always desired that a novel compound having an antiallergic activity or an antiinflammatory activity
`be developed.
`
`10
`
`,.
`
`20
`
`'
`
`'
`
`-.
`
`Ii
`
`l
`
`I
`
`25 ' Summary gt th_e Invention
`
`The present invention relates to a diben2[b,e] oxepin derivative represented by the formula (I):
`
`30'
`
`N
`
`}f- (C32) :1"
`
`35
`
`(I_)
`
`wherein A represents a hydroxymethyl. a lower alkoxymethyl a triphenylmethyloxymethyl a lower al-
`kanoyloxymethyl a lower alkanoyl. a carboxy. a lower alkoxy carbonyl, a triphenylmethyioxycarbonyl. -
`CONR .8, (wherein R. and R, are the same or different and represent hydrogen atom or lower alkyl) 44-
`dimethyl-Q-oxazoline~2‘yl group or oCONHOH; Y represents -(CH,)m-, ~CHR,-(CH,)mpr ~CR. =CR§‘(CH2)m'
`which is substituent at 2oor 3-position of the mother nucleus (wherein Ft, represents a lower alkyl. R. and F1;
`are the same or different and represent a hydrogen atom or a lower alkyl. m is O.
`l. 2, 3 or 4. and the left
`side of the group of Y mentioned above is bound to benzen nucleus); X represents = N-. = CH-or ~CH,-; n
`is 0.
`l. 2. 3 or 4; 2 represents 4-methylpiperazino. 4-methylhomopiperazino. piperidino. pyrrolfdino,
`thiomorpholino. morpholino. or -NFl.R,,(wherein Rt and R, are the same or different and represent a
`hydrogen atom or a lower alkyi); and 2:: means a single bond or double bond [hereinafter
`referred to as CompOund (l) and Compounds with other formula numbers are hereinafter likewise referred
`to] and a pharmaceutically acceptable salt thereof. The present invention further pertains to a phannaceuti~
`cal composition containing an effective amount of Compound (l) or a phannaceutically acceptable salt
`thereof as an active ingredient, and a carrier or an excipient.
`The present Compound (l)Is useful for treatment of allergic conditions and inflammation.
`
`‘
`
`,
`
`40
`
`45
`
`50
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 004
`
`4.
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 004
`
`

`

`
`
`O 235 796
`
`Detailed Description 91 th_e Invention
`
`isopropoxy.
`
`In the definition of each group of fomrula (l). the lower alkyl group includes straight or branched chain
`alkyl groups having I to 6 carbon atoms for example. methyl. ethyl. n«propyl iso-propyl. n-butyl. etc. In the
`definition of the group A lower alkyl moiety of lower alkoxymethyl group and lower alkoxycarbonyl group
`has the same meaning as previously defined.
`The lower alkoxymethyl group includes methoxymethyl. ethoxymethyl. n-propoxymethyl.
`etc. and the lower alkoxycarbonyl group includes methoxycarbonyl. ethoxycarbonyl. etc
`In the definition of the group A the lower alkyl moiety of lower alkanoyl group and lower alkanoylox-
`ymethyl group has the same meaning as previously defined.
`‘ The lower alkanoyl group includes tormyl. acetyl. etc. and the loweralkanoyloxymethyl group includes
`iormyloxymethyl. acetyloxymethyl. etc
`includes pharmaceutically acceptable acid
`The pharmaceutically acceptable salt of Compound (I)
`addition salt metal salt ammonium salt organic amine addition salt, amino acid addition salt. etc.
`The pharmaceutically acceptable acid addition salt of Compound (It includes inorganic acid salts such
`as hydrochloride. sulfate phosphate, etc” and organic acid salts such as acetate maleate. fumarate.
`tamate. citrate. etc. The pharmaceutically acceptable metal salt includes alkalimetal salts such as sodium
`salt potassium salt. etc.. alkaline earch metal salts Such as magnesium salt. calcium salt. etc. and alminium
`salt. zinc salt. etc The phannaceutically acceptable organic amine addition salt includes addition salt of
`morpholine and piperidine and the pharmaceutically acceptable amino acid addition salt includes addition
`salt of lysine. glysine phenylalanine. etc.
`Compound (I)Is prepared by using a compound represented by theformula (ll):
`
`(II)
`
`0 I
`
`0
`
`wherein Y and A have the same meanings as previously defined or' a compound represented by the tormuia
`(Ill):
`'
`
`(III)
`
`.10
`
`15
`
`2O
`
`25
`
`.50
`
`35
`
`wherein Y and A have the same meanings as previously defined as the starting compound. Compound (II)
`"is disclosed in J. Med. Chem. l9, 941 0976). ibid. 2_Q. I499 0977) and JPA~2l679/83.
`Compound (Ill) wherein ~Y~A is -COOH is disclosed in JP-A-2l679/83 and the other Compounds (Ill) can
`be prepared according to the method described in the publication though they do not occur in the
`publication.
`-
`
`45
`
`The process for preparing Compound (I)Is explained depending on the kind of the group X.
`
`Process A
`
`[Synthesis of Compound (I) wherein X‘is = CH-(Part l)]
`
`The carboxy group of Compound (lie) is protected according to the following reaction scheme.
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 005
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 005
`
`

`

`O 235 796
`
`SOC12
`C—Y-COOH—-——-———
`
`H(.I
`
`10
`
`15
`
`socl2
`
`.
`
`.
`
`"
`
`'0
`
`i
`
`0
`I
`
`0
`( V)
`
`O
`
`.
`
`CH3
`
`/— 0H
`VTCHB
`CH3
`OH
`
`In the formulae, Y has the same meaning as previously defined and Compound (Ila) is included in
`Compound (II)
`(compounds with an alphabet suffix toltowing formula number are likewise included in
`compounds with common formula no).
`Compound (lla)'Is reacted with l to 5 equivalents of thionyl chloride and I to 5 equivalents of 2-amino-2-
`methyl-l-propanol on the basis of Compound (Ila)
`in an inert solvent such as methylene chloride if
`necessary in the presence of a base such as tn’ethylamine at a temperature of from 0" C to room
`temperature for l -24 hours to form Compound (IV). Compound (IV) can also be obtained by reacting
`Compound (Ila) with thionyl chlorideIn advance and then with 2-arnino-2-mettwyhtpropanol.
`Compound (IV) is reacted with l -5 equivalents of thionyl chloride”In an inert solvent such as methylene
`chloride toluene and benzene at a temperature of from 0°C to room temperature for l -24 hours to form
`Compound (V).
`
`Compounds (la) and (lb) can be prepared from Compound (V) according to the following reaction -
`' scheme.
`
`20
`
`25
`
`so
`
`35
`
`40
`
`45
`
`50
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 006
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 006
`
`

`

`o 235' 796
`
`o
`HalMg(CH )
`2 '(VI)
`2 n+1
`O--Y—<\ w
`N
`
`(CH2)n+lZ
`
`G—r—t
`
`N
`
`H
`
`_
`
`o
`
`—H o
`
`—2—>
`
`2
`
`( A)
`ca
`_
`2 n
`.
`
`o—v—t 1
`
`o
`
`N
`
`o
`(V)
`301
`
` o
`
`70
`
`I
`
`15
`
`20
`
`25
`
`30
`
`_
`35'
`
`( Ia)
`
`..
`
`H20
`
`H
`
`/(CH2)nZ
`
`Gey—cozaa
`
`o
`
`( Ib)
`
`In the formulae Y. Z. and n have the same menaings as previously defined R. is hydrogen or a lower
`' alkyl group. Fi‘. is a lower alkyl group and Hal is halogen.
`As used herein the term lower alkyl has the same meaning as that of lower alkyl in each group oi
`formula (I).-Halogen includes chlorine.- bromine and iodine
`in an inert solvent such as
`Compound (V)
`is
`reacted with |
`-5 equivalents of Compound (VI)
`'tetrahydrofuran and dielhyl ether under atmosphere of an inert gas such as nitrogen and argon to form
`Compound (VII). The reaction is carried out at a temperature of from 0° C to room temperature and is.
`usually completed in I -24 hours.
`-Comp0und (VII) is reacted with I -5 equivalents of thionyl chloride or phosphoryl chloride in an inert
`solvent such as methylene chloride in the presence of a base such as pyridine to form Compound (la). The
`reaction is carried out at a temperature of from 0°C to room temperature and is completed in I '24 hours.
`Compound (la) is incubated in an alcohol containing water, such as aqueous methanol solution, in the
`presence of an appropriate acidic catalystsuch as ptoluenesullonic acid at a temperature of from room
`temperature to the boiling point of the solvent to form Compound (lb) wherein R. is H The reaction is
`completedIn l -24 hours.
`-
`Compound (VII) is incubated in an alcohol of R.’0H in the presence of an appropriate acidic catalyst
`such as p-toluenesulionic acid at a temperature of from room temperature to the boiling point of the solvent
`to form Compound (lb) wherein R. is a lower alkyl. The reaction is completed in I -24 hours.
`
`‘
`
`Process _B_
`
`* [Synthesis of Compound (I) wherein X is = CH-(Part 2)]
`
`The carboxy group-oi a compound represented by the formula (lla)-’can’be converted to a lower
`alkoxymethyl group or a trityloxymethyl group according to the following reaction scheme.
`.
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 007
`
`45
`
`'50
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 007
`
`

`

`1O
`
`15
`
`'20
`
`30
`
`35
`
`50
`
`55
`
`0 235 796
`
`o
`
`0
`
`
`O Y—COZH
`
`(Hal LiAlH. 4
`
`OH
`
`G—Y-CHZOH
`
`0
`
`(VIII)
`
`R908
`dig—w432062911)3 @Cfic:
`
`C(Ph) 3C1
`
`
`
`Y~CZZZOR9
`
`(IX)
`
`'
`
`( X)
`
`Vidation
`
`'
`
`O
`
`O
`
`_ cm
`
`'-
`
`
`
`— Oxidation
`
`Y'Ci-IZORQ'
`
`In the formulae. Y has the same meaning as previously defined, R, is a lower alkyl group and R,’ is a
`trityl group or a lower alkyl group. The term lower alkyl has the same meaning as that of lower alkyl in each
`group in formula (I).
`Compound (lla) is reduced with l -5 equivalents of lithium aluminium hydride in ,tetrahydrofuran at a
`temperature of from 0°C to room temperature for'l ~24 hours to form Compound (Vlll).
`Compound (Vlll) is reacted with l -5 equivalents of trityl chloride in pyridine at a temperature of from
`room temperature to l00°C for I -24 hours to form Compound (DO.
`-
`Compound (IX) is Oxidized with l -5 equivalents of an appropriate oxidizing agent such as potassium
`permanganate and pyridinium chlorochromate in an inert solvent such as methylene chloride and acetone to
`form Compound (XI) wherein R. is trityl. The reaction is carried out at a temperature of from 0°C to the
`boiling point of the solvent and is completed in l ~24 hours.
`Compound (Vlll) is incubated in an alcohol of Fi.OH in the presence of an appropriate acidic catalyst
`such as sulfuric acid at a temperature of from room temperature to the boiling point of the solvent to form
`Compound (X) The reaction is usually completed in l-24 hours
`COmpound (X)Is oxidized with l ~5 equivalents of an appropriate oxidizing agent such as Jones reagent
`in an inert solvent such as acetone to form Compound (XI) wherein R; is a lower- alkyl. The reaction Is
`carried out at a temperature of from 0°C to the boiling point of the solvent and is usually completed in l -24
`hours
`
`The compounds represented by the formulas (to) and (Id) and if desired. the compound represented by
`the formula (le) can be synthesized from Compound (XI) according to the following reaction scheme.
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 008
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 008
`
`

`

`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`4D
`
`45
`
`50
`
`55
`
`_ o 235 796
`
`(v1)
`
`C)
`
`o
`
`.(XI)
`
`Y-CHZORQ'
`
`inalugtcaztn+lz
`(éflz'tmlz
`
`H0
`
`9 (XII)
`
`OR'*---~—---~---——-\2,
`
`Y~CH2
`
`_
`
`H
`
`(CH
`
`
`
`in the formulae, Y, 2, R9,. n and Hal have the same meanings as previously defined.
`Compound (Xi) is reactedwith Compound (VI) which is Grignard reagent according to the same manner
`“as in the reaction step from Compound (V) to Compound (VII) in Process A to form Compound (XII).
`Compound (Xll) is subjected to reaction according to the same manner as in thereaction step from
`Compound (Vll) to Compound (la) in Process A l0 form Compound (tc).
`Compound (lc) is incubated in a solvent -.‘ontaining water such as aqueous dioxane in the presence of
`an appropriate acidic catalyst such as p-toluenesullonic acid at a temperature of lrorn room temperature to
`the boiling point of the solvent to form ComDOuttd (id). The reaction is usually completed in l -24 hours.
`Compound (Id) can also be obtained in one step by incubating Compound (Xll) in a solvent containing
`water such as aqueous dioxane in the presence- oi anappropriate acidic catalyst such as sulfonic acid at a
`temperature of from room temperature to the boiling point of the solvent. The reaction is usually completed
`in l -24 hours.
`_
`if desired. Compound (Id) is oxidized With l -5 equivalents of an appropriate oxidizing agent such as
`' Jones reagent in an inert solvent such as acetone to form Compound (ie). The reaction is carried out at a
`temperature of from 0°C to the boiling point of the solvent and is usually completed in .I -24 hours.
`
`’
`
`Process g;
`
`[Synthesis of Compound (I) wherein X is =CH-(Pan 3)).
`
`9
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 009
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 009
`
`

`

`O 235 796
`
`0
`
`0
`(11b)
`
`
`Q Y—A' + 91239 =CHfCHZInZ
`(an)
`
`3..
`
`(c}§2)nz
`
`*9
`
`C—-—-'-— Y -A'
`
`o (
`
`If)
`
`In the formulae. Y. Z. and n have the same meanings as previously defined. A’ represents the groups
`falling within the definition of A but lower alkanoyl group.
`in an inert solvent such as
`Compound (lib)
`is reacted with I
`-5 equivalents of Compound (XIII)
`tetrahydroiuran under atmosphere of an inert gas such as nitrogen and argon at a temperature of from 0°C
`to room temperature for l ~24 hours to form Compound (h).
`Compound (XIII) which is ylide, can be prepared according to the method described in CA. fl l6366a ~
`(I965).
`.
`
`PhBP + Hal (CH2 )n:lHalH Ph3Pv(CH2)n+lHal
`
`- Hal
`
`.(XIV)
`
`'
`
`_
`
`(XV)
`
`+
`
`———-————-—-——=l)HZ
`
`2) ma
`
`g
`-Ha
`13:13.(c:212)n_‘_l
`(XVI)
`
`z
`
`1”
`
`“1
`- (as: )q
`
`In the formulae. Hal n and 2 have the same meanings as previously defined and q is I or 2
`Compound (XIV) is reacted with an equivalent of triphenylphosphine in toluene at reflux of the solvent
`for l ~24 hours to form Compound (XV).
`Compound (XV) is reacted with 1 ~55 equivalents of HZ in ethanol at reflux of the solvent for I ~24 hours
`and excess H2 is distilled away under reduced pressure. After the addition of I -5 equivalents of HHal on
`the basis of Compound (XV) the mixture is incubated at a temperature of from [PC to the boiling point of
`the solvent for l ~24 hours to form Compound (XVI) whichIs Wittig reagent.
`Compound (XVI) is treated with l ~2 equivalents of an appropriate base such'as n-butyl lithium in an
`inert solvent such as tetrahydrofuran under atmosphere of an inert gas such as nitrogen and argon to form
`ylide (XIII). The reaction is carried out at ~78°C - room temperature and is usually completed in l ~24 hours.
`
`Process Q
`
`{Synthesis of Compound (I) wherein X is = CH-(Part 4)]
`
`10
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 010
`
`1D
`
`15
`
`20
`
`25
`
`30
`
`35
`
`45
`
`50
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 010
`
`

`

`O 235 796
`
`.
`
`’
`
`~
`
`(3
`formaldehyde
`——Y -A + or polymerized +
`o“\,) -
`_
`formaldehyde
`(III)
`
`H2
`
`'
`
`H..'L/\z
`
`
`
`(Igl
`
`In the formulae. Y. Z and A have the same meanings as previously defined.
`The process is known as Prince reaction [New Experimental Chemical Course (Maruzen), Vol. l4
`Synthesis and Reaction of Organic Compound lll page i375 (i9T/)]._
`Compound (ill) I to 5 equivalents of formaldehyde and |
`to 5 equivalents of H2 are subjected to
`reaction in an inert solvent such as tetrachloroethane in the presence oi an acid or reaction in an acid as,
`such serving as a solvent under atmosphere of an inertgas such as nitrogenand argon to yield Compound
`(g)
`
`trioxane, etc. The acid
`The formaldehyde or polymerized formaldehyde includes p-iormaldehyde.
`includes acetic acid, trichloroacetic acid, trifluoroacetlc acid, etc. The reaction is carried out at a tempera-
`ture of from room temperature to the boiling point oi the solvent and is completed in |_-24 hours.
`Compound (ill) which is the starting material can be prepared according to the process described in JP-
`A-2l679/83, as shown below.
`
`-
`
`'
`
`o
`
`
`
`(I b)-
`
`(XVII
`
`5
`
`70
`
`15
`
`29
`
`25
`
`so
`
`as
`
` 4a
`
`(Illa)
`
`‘5
`
`5°
`
`55
`
`to 5
`to 5 equivalents oi methyltriphenylphosphonium bromide "and |
`l
`is. Compound (lib)
`That
`equivalents of n‘butyl lithium on the basis of Compound (lib) are subjected to reaction in an inert solvent at
`from ~78? C to room temperature for l to 5 hours to yield ylide (XVll) which is reacted with an equivalents of
`Compound (lib) in an inert solvent at from .78" C to room temperature under atmosphere of an inert gas for
`l to 24 hours to yield Compould (lila).
`'
`‘
`’
`The inert gas includes nitrogen, argon etc. and the inert solvent includes tetrahydrofuran. etc.
`The group A'
`in Compound (illa) can easily. be converted to a lower alkanoyl group as is stated in
`Process l and therefore. Compound (lll) can easily be prepared.
`
`Process g
`
`[Synthesis of Compoundll) wherein X is = N-]
`
`11
`
`Ayla Pharma LLC (IPR2020-00295-) EX. 1035 p. 011
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 011
`
`

`

`1O
`
`15
`
`20
`
`25
`
`45
`
`50
`
`55'
`
`0 235 796
`
`O
`
`0
`(1:23)
`
`Q— Y-A' + HZN (CI—22) Hz
`(XVIII)
`
`
`
`
`
`(Ih)
`
`Compound (llb) and I to lo equivalents of Compound (XV!!!) are subjected to reaction in an inert solvent
`such as benzene in the presence of I to lo equivalents of titanium tetrachloride at from 0°C to the boiling
`point of the solvent under atmosphere of an inert gas such as nitrogen and argon lor l to 48 hours to yield
`Compound (lh).
`-
`
`Process 5
`
`- [Synthesis of Compound (I) wherein x is ~CH,—(Part I)]
`
`
`-——-——____.._.'>I
`
`Chlorination '
`
`I
`
`(XX)
`
`Reduction
`
`OH
`
`O
`
`0
`(>4 -< 7
`
`(XIX).
`
`
`
`HalMglCHZ) n+1_Z (V?!
`
`0 Y4?)
`
`CH
`
`~\ NF?
`
`DE]
`
`~
`“:’1-
`:1
`C',/\\a zln
`
`2
`
`""9
`
`Y—<:1+fo_ 0,944" {0233 I
`
`(:3)
`
`In the formulae. Y. Z. n, R. and Hal have the same meanings as previously defined.
`Compound (V) is reduced with I to 5 equivalent of lithium aluminium hydride or sodium borohydride'in
`an inert solvent such as tetrahydrofuran and methanol at from 0°C to room temperature for l to 24 hours to
`yield Compound (XIX).
`-
`Compound (XD() and I
`to 5 equivalents of thionyl chloride or phosphoryl chloride are subjected to
`reaction in an appropriate base such as pyridine at from 0"C to room temperature to yield Compound (>00.
`
`12
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 012
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 012
`
`

`

`0 235 796
`
`Compound (XX) and I to 5 equivalents of Compound (Vl) are subjected to reaction in the same manner
`as in the reaction step from Compound (V) to Compound (VII) ingProcess A to yield Compound (Ii).
`Compound (Ii) is subjected to reaction in the same manner as in the reaction step from Compound -
`(Vll) to Compound (lb) or the reaction step irom Compound (Ia) to Compound (lb) in Process A to yield
`Compound (lj).
`,
`
`,
`
`5
`
`Process 33
`
`10
`
`[Synthesis of Compound (I) wherein X is -CH,-(Part 2)]
`
`oe
`
`-
`
`'
`
`'
`
`-
`
`Cl
`
`g C 2—7 32
`
`
`
`V'
`
`o
`(xxx)
`
`>
`
`
`-~ Chlorination
`
`
`-
`
`‘
`
`.7
`
`9
`
`
`
`_
`
`‘
`
`.
`
`C—y-cazoag'
`
`'
`
`o
`(XXII)
`
`_
`
`'
`
`Z
`
`’5
`
`”2°
`
`25
`
`30
`
`35
`
`40
`
`HalMg (CH2 )n+12 (VI)
`
`r O
`.
`
`,
`
`*
`
`+.
`H
`——>
`
`g
`» CH2
`
`(C32)
`
`2
`
`»
`
`-
`.'
`Q—y—CHZOH
`
`
`
`Oxidize-
`tion
`
`-‘
`
`caz- tcazl nz '
`g
`
`,
`Gr—Y-CH OR '
`o /
`2
`9
`(IR)
`
`(CH )
`/ ' 2 2
`CH2
`
`'
`' Owy-coza
`
`.
`
`(12)
`
`‘
`
`V
`
`(Im)
`
`‘
`V
`_
`Compound (XXI) is subjected to chlorination in the same manner as in Process F to yield Compound
`(XXII) Compound (XXll) and Compound (Vl) are subjected to reaction in the same manner as in Process F
`to yield Compound (lk) Compound (IR) is treated in the same manner as in Process B to term Compound ~
`(I!)
`Compound (it) is further treated to form Compound (lm)
`,
`Compound (IX)rs included in the definition of the starting material (XXI).
`Compound (XI) is reduced with l to 5 equivalents of lithium alminium hydride or sodium borohydride in
`an inertsolvent such as tetrahydroturan and methanol at from 0°C to'room temperature for I to 24 hours to
`yield Compound (XXI). ,
`r
`'
`'
`
`Process )1
`
`[Synthesis of Compound (I) wherein X is -CH,-(Part 3)]
`
`Compound (I) wherein X is —CH2-can also be‘prepared by subjecting Compounds (la) -(lg) obtained by
`. the Processes A -D to reduction such as hydrogenation using paradium—carbon as catalyst.
`The intermediates and the desired compounds in each of the processes described above can be
`purified and isolated by a purification method which is usually used in the field of organic chemical.
`synthesis. such as filtration. extraction with organic solvent such as ethyl acetate and methylene chloride,
`drying. concentration. recrystallization. column chromatography. etc.
`
`,
`
`'
`
`'
`
`13
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 013
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 013
`
`

`

`0 235 796
`
`-(lh) obtained in each of the processes described above. with regard to
`- Out of Compounds (la)
`stereochemistry at ll-position of dibenzib.e]oxepin. Compounds (Ia), (lb). (lc). (Id). (lg) and (lh) are apt to be
`formed as a trans-tom and Compound (l,) is apt to be formed as a cis-form. with high frequency compared
`with the other form.
`When Compound (I) except Compounds (li) -(lm) is produced as a cis'trans mixture. Compound (I) is
`separated and purified by an appropriate method which is usually used in the field of organic chemical
`synthesis, such as column chromatography. recrystallization. etc.
`‘
`if desired. cis-form can be converted to transform. For example, cis-torm is added to an acetic acid and
`the mixture is heated at reflux in the presence of an appropriate catalyst such as p~toiuenesuiionic acid for i
`—24 hours to form trans-form.
`
`WIth regard to the denotation of cis-form (or cin-form) and trans form (or anti-form) of Compound (I).
`Compound (I) wherein the substituent bound to the double bond is on the same side as oxygen of oxepin.
`is cis-tom'I (or cin-form) and Compound (l) wherein the substituent is on the opposite side is trans-form (or
`anti-form).
`»
`- Further. if cis~or trans-form is denoted according to E -Z expression, cis-form (or cin-fonn) is Z-tom'I
`and trans-form (or anti—form) is E-form.
`For example. the compound represented by the following tonm'Ila is cis-form (or sin-form or Z-fon'n).
`
`H
`
`(CH2)n-Z
`
`Table l shows examples of Compound (l) or phannaceutically acceptable salts thereof and Table 2
`shows the structural formula thereof.
`Table 3 shows characteristic signals in NMR and Table 4 shows retention time in HPLC.
`
`1O
`
`15
`
`20
`
`25
`
`30
`
`45
`
`14
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 014
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 014
`
`

`

`10
`
`15-
`
`20
`
`x
`
`-30
`
`-35
`
`45
`
`50
`
`55
`
`0 235 796
`
`Table l
`
`
` Methyl cis-ll-(3edimethylaminopropylidene)-
`
`6,11-dihydrodibenz[b;e]oxepin-Z—carboxylate
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ethyl trans—ll~(3-dimethylamihopr0pylidene)-
`6,11-dihydrodibenz{b}e]oxepin-2-carboxylate
`
`Trané-ll—(3~dimethjlaminopropylidenef—6,ll-
`dihyérodibenz[b.e]oxepin-2-carboxylic acid
`
`
`
`Methyl trans-li~(3-diethylaminopropylidene)-
`6,11-dihydrodibenz[b.e]oxepin—Z-carboxylate
`
`
`trans—11-(3-dimethylaminopropylidene)r
`Methyl
`6,ll~dihydrodibénz[b,e]oxepin-Z—carboxylate
`
`Ethyl cis-llh(3-dimethylaminopropylidene)~6,ll~
`
`dihydrodibenz[b,e]Oxepin-Z-carboxylate
`
`
`
`Cis-ll—(3—dimethylaminopropylidene)-6;ll-
`
`dihydrodibenz[b.e]oxepin-2~carboxylic acid
`
`
`
`
`
`
`Methyl cis—ll-(3~diethy1aminopfopylidene)—6;ll-
`
`dihydrodibenz[b,e]oxepin~2-carboxylate
`
`
`
`
`Cis-ll—(3~diethylaminopropylidene)~6,ll~
`
`dihydrodibenzLb,e]oxepin~2-carboxylic acid
`
`
`
`
`
`
`Trans-ll-(3-diethylaminopropylidene)~6,ll-
`dihydrodibenz[b,e]oxepin-2-carboxylic acid
`
`
`'Methyl cis-ll—(3-pyrrolidinopropylidene)—6,ll-
`dihydxodibenz(b,eloxepin—charboxylate
`
`trans—ll—(3—pyrrolidinopropylidene)-
`Methyl
`
`6,11-dihydrodibenz[b.e]oxepin~2~carboxylate.
`
`
`
`Cis—ll-(3-errolidinopropylidene)-6,ll~
`dihydrodibenz{b,e]oxepin-2-carb0xylic acid
`
`
`
`
`
`
`
`
`
`
`Trans—ll-(3—pyrrolidinopropy1idene)—6,ll-
`dihydrodipenz[b,e]oxepin-2-carboxylic acid
`
`15
`
`Ayla Pharma LLC (IPR2020-00295) EX
`
`.1035 p. 015
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 015
`
`

`

`1O
`
`15
`
`20
`
`25
`
`30
`
`35
`
`45
`
`50
`
`55
`
`0 235 796
`
`
`Methyl cis-ll—(4-dimethylaminobutylidene)-
`6,11-dihydrodibenz[b,e]oxepin—Z-carboxylate
`
`Methyl trans-ll-(4-dimethylaminobutylidene)-
`6,11—dihydr0dibenz(b,e]oxepin—Z-carboxylate
`
`
`
`
`Cis-ll-(4-dimethylaminobutylidene)-6,ll—
`dihydrodibenz[b,e]oxepin«2—carboxylic acid
`
`
`
`
`
`
`Trans—ll—(4~dimethylaminobutylidene)'6,ll—
`dihydrodibenz[b,e]oxepin-2—carboxylic‘acid
`
`
`
`
`
`
`
`
`
`
`
`Methyl trans—ll—[Z-(4-methylpiperazino)‘
`
`ethylidene1—6,ll-dihydrodibenz[b,e]oxepin-2~
`
`carboxylate
`
`Methyl cis—ll—[Z-(4-methylpiperazino)-
`ethylidene]—6,ll-dihydrodibenz[b,e]oxepin—2-
`carboxylate
`
`
`
`Cis~ll-[2—(4—methylpiperazino)ethylidene]-
`6,1l—dihydrodibenz[b,e]oxepin—2-carhoxylic acid
`
`Trans~ll—[2-(4—methylpiperazino)ethylidene]-
`6,11-dihydrodiben2[b.eloxepin—Z-carboxylic acid
`
`Methyl cis—ll-(Zimorpholinoethylidene)~6,ll—
`
`
`
`Methyl trans-ll—(2-morpholinoethylidene)-6,ll-
`
`
`
`
`
`dihydrodibenz[b,e]oxepin-Z-carboxylate
`dihydrodibenz[b,eloxepin—Z—carboxylate
`
`
`
`
`
`Cis-ll~(2-mcrpholinoethylidene)~6,11-
`dihydrodibenz[b.e]oxepih—2—carboxylic acid
`
`
`
`
`
`
`
`Trans-ll—(2~morpholinoethylidene)-6,ll-
`dihydrodibenz[b,e]oxepin—2-carboxylic acid
`
`
`
`Methyl cis-ll-(2-thiomorpholinoethylidene)-
`6,ll-dihydrodibenz[b,e]oxepin—Z-carboxylate
`
`
`Methyl trans-ll-(Z-thiomorpholinoethylidene)-
`6,11—dihydrodiben2[b,e]oxepin—2~carboxylate
`
`
`Cis—ll-(2~thiomorpholinoethylidene)-6,ll—
`
`
`dihydrodibenz[b,e]oxepin—2—carboxylic acid
`
`
`Ttans-ll-(2—thiomorpholinoethylidene)-6,1l-
`dihydrodibenzlb,e]oxepin-Z—carboxylic acid
`
`
`
`
`16
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 016
`
`
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 016
`
`

`

`10‘
`
`fi
`
`20
`
`25
`
`30
`
`35
`
`45‘
`
`5O
`
`55
`
`0235796
`
`
`
`Methyl cis- ll (2—pyrrolidinoethylidene)~6, ll-
`dihydrodibenzib, e]oxepin- 2-carboxylate '
`
`trans—~11-(2—pyrrolidihoethylidene)-
`Methyl
`6,11-dihydrodibenz[b,e]oxepin-Z—carbox111ate
`
`~Methyi cis—ll—(2-piperidinoethylidene)-6,ll-
`dihydrodibenz[b,e]oxepin~2-carboxylate
`
`Methyl trans-ll-(2—piperidinoethylidene)-6}ll—
`dihydrodibenz[b.e]oxepin—Z—carboxylate
`
`trans—ll—(3-dimethylaminopropylidene)-
`
`
`
`
`
`
`
`
`
`
`'
` Methyl cis--ll- (3—dimethylaminopropylidene)-
`
`
`6, ll——dihydrodibenz[b, eloxepin-Z-acetate
` “Methyl transll- (3-dimethylaminopropylidene)-
`-
`6, ll--dihydrodibenz[b, eloxepin—Z—~acetate
`
`
`
`Ethyl cis—il~(3-dimethylaminopropylidene)—6,ll*
`
`dihydrodibenz[b,e]oxepin—2—acetate
` Ethyl
`6,1l-dihydrodibenz[b,e]oxepin—2—acetate
`
`Cis-ll~(3~dimethylaminopropyiidene)-6,ll=
`
`dihydrodibenz[b.eloxepin-Z-acetic acid
`_..J_...
`.
`J.......
`Tr:n_s—l'|_~(3-d1_methu1 :m
`
`dihydrodibensz, eloxep'h
`
` Methyl cis—ll— (4-dimet_hylamin‘obutylidene) —6 , 11-
`
`
`dihydrodibenz{b,eloxepinj2-acetate
` Methyl
`6,ll—dihydrodibenz[b,e]oxepin—2eacetate
`
` Cis—ll-(4-dimethyiaminobutylidene)—6,ll-
`
`
`dihydrodibenz[b,e]oxepin-2-acetic acid
`
`
`
`
`
`
`trans-ll-(4~dimethylaminobutylidene)-
`
`Trans—ll—(4~dimethylaminobutylidene)—6,ll-
`dihydrodibenz[b,e]oxepin-2—acetic acid
`
`' Methyl cis--ll- (3--pyrrolidinopropylidene)-6, ll-
`dihydrodibenz[b, eloxepin-Z- acetate '
`
`
`Methyl trans-ll-(3-pyrrolidinopropylidene)-
`6,11—dihydrodibenz[b,e]oxepin—2—acetate
`
`
`17
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 017
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 017
`
`

`

`O 235 796
`
`
`
`Cis—ll-(3-pyrrolidinopropylidene)~6,ll—
`dihydrodibenz[b.eloxepin-Z-acetic acid
`
`Traps-ll-(3-pyrxolidinopropylidene)-6,ll-
`
`Trans-ll—{2;{4—methylpiperazino)-ethylidene~
`6,11-dihydrodibenz[b,eloxepin-2-acetic acid
`
`Methyl cis—B-[ll—(3~dimethylaminopropylidene)—
`6,11—dihydrodibenz[b,e]oxepin—2~yl]—prop§onate
`
`Methyl trans-3-[ll~(3-dimethylaminopropyli-
`dene)-6,ll~dihydrodibenz[b,e]oxepin-2—yl]-
`
`
`
`
`
`
`
`
`
`dihydrcdibenz[b,e]oxepin~2~acetic acid
`
`
`Methyl cis-ll—[2—(4—methylpiperazino)-
`ethylidene-G,ll—dihydrodibenz[b,e]oxepin-2—
`,
`acetate
`
`
`Methyl
`trans~ll~[2-(4—methylpiperazino)-
`ethylidene—G,ll-dihydrodibenz[b,e]oxepin-2-
`
`acetate
`
`
`
`Cis-ll-[Ze(4—methylpiperazino)—ethylidene-
`6,11—dihydrodibenz[b,e]oxepin-2-acetic acid
`
`
`
`
`
`
`
`
`propionate
`
`
`
`
`Cis-B—[ll—(3~dimethylaminopropylidene)~6,ll-
`
`dihydrodibenz[b,e]oxepin-2—ylj-propionic acid
`
`
`
`
`
`Trans—3-[ll-(3-dimethylaminopropylidene)—6,ll~
`dihydrodibenz[b,e]oxepin—2~yl]-propionic acid
`
` 4
`
`
` Cis-ll-(3-dimethylaminopropylidene)-6,ll-
`
`Methyl cis~ll~(3-dimethylaminopropylidene)-
`6,11—dihydrodibenz[b,e]oxepin-3-aoetate
`
`Methyl trans-ll-(3-dimethylaminopropylidene)*
`
`
`
`
`
`6,114dihydrodibenz[b.e]oxepin~3-acetate
`dihydrodibenz[b,e]oxepin-3-acetic acid
`
`
`Trans—ll-(3-dimethylaminopropylidene)-6,llv
`dihydrodibenz[b,e]oxepin-3-acetic acid
`
`
`
`Cis-ll—(3-dimethylaminopropylidene)~2—(2-
`hydroxyethyl)~6,ll-dihydrodibenz[b,e]oxepin
`
`
` Trans-ll—(3-dimethyiaminopropylidene)-2—(2-
`
`hydrquethyl)-6,ll—dihydrodibenz[b,e]oxepin
`
`
`
`18
`
`Ayla Pharma LLC (IPR2020-00295) EX. 1035 p. 018
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`4O
`
`45
`
`55
`
`Ayla Pharma LLC (IPR2020-00295) Ex. 1035 p. 018
`
`

`

`1O
`
`15
`
`.20
`
`25
`
`3O
`
`35
`
`45
`
`50'
`
`55
`
`0235796.
`
`32
`
`CisTIl-(3-dimethylaminoprcpylidene)~2~(2~
`triphenylmethyloxymethyl)~6,ll-dihydrodibenz_
`[b,e]oxepin
`'
`_
`
`Trans~ll~(3-dimethylamihcpropylidehe)~2—(2-
`triphenylmethyloxymethyl)-6,ll-dihydrodibenz—
`[b,e]oxepin
`‘
`
`Cis-ll—(3-dimethylaminopropylidene)-2-(3-
`hydroxy